Business Context and Reporting Period
This Form 8-K is a current report filed by Pieris Pharmaceuticals, Inc. (PIRS) on May 15, 2023. The filing addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the company's compliance with listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the notice: the closing bid price of the Common Stock fell below $1.00 per share for 30 consecutive business days.
Material Changes
The material event reported is the receipt of a written notice from Nasdaq indicating the company no longer meets the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). This notice has no immediate effect on the listing, and the stock continues to trade under the symbol "PIRS" on The Nasdaq Capital Market.
Outlook, Risks, and Contingencies
- Compliance Period: The company has an initial 180-calendar-day period (until November 13, 2023) to regain compliance.
- Compliance Requirement: To regain compliance, the closing bid price must meet or exceed $1.00 per share for a minimum of 10 consecutive business days.
- Contingency Plan: If the company fails to regain compliance by the initial deadline, it may be eligible for an additional 180-day period if it meets other listing standards and effects a reverse stock split if necessary.
- Risks: There is no assurance the company will regain compliance or that an extension will be granted. Failure to cure the deficiency could result in delisting. An appeal to a Nasdaq Listing Qualifications Panel is possible but not guaranteed to be successful.
Investor Verification Checklist
- Verify the current closing bid price of PIRS stock relative to the $1.00 threshold.
- Monitor the company's announcement of a potential reverse stock split if the initial compliance period expires without success.
- Check for any subsequent filings regarding the status of the compliance period or appeals to the Nasdaq Listing Qualifications Panel.
- Review the company's liquidity position in recent 10-Q or 10-K filings to assess the ability to fund operations while addressing the listing deficiency.